Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AdAlta (ASX:1AD) says its automated IRO manufacturing strategy has gained commercial validation after Oribiotech secured a major long-term customer under a 10-year agreement worth up to US$120 million.
Sept 18 (Reuters) — Adalta Ltd: Oribiotech Deal Validates Adalta Manufacturing Strategy Oribiotech Signs 10-year Partnership Worth Up To $120 Million For Iro Platform Further company coverage: 1AD.AX (Reuters.Briefs@thomsonreuters.com;)
Adalta Ltd (ASX:1AD) said its Oribiotech deal validates its manufacturing strategy.